Ann: Appendix 3Y Director's Interest Notice, page-3

To stump up $300k at this point of the journey is a great sign.

At 3.7c the market has priced in meagre domestic growth and zero revenue from international expansion.

10M would put him in the Top20.

With this commitment it suggests the opportunities are on the not to distant horizon.

According to their announcements, PDX Inc integration should be complete in the coming weeks. This opens up 15% of pharmacies in the US (10,000+).

Last month they also received approval to integrate with the UK dispense systems, of which there are only 3.

I suspect into early next year EBOS will get return on their 5.75c per share investment.